

(Correction) Partial Correction to “Notice of Re-prioritization of In-house Drug Discovery Pipelines and Change in Use of Funds Raised at the Time of Listing”

Noile-Immune Biotech Inc. (hereinafter “Noile-Immune”) hereby announces that the matters needed to be partially corrected as follows, in which Noile-Immune announced timely disclosure announced on June 28, 2024, “Notice of Re-prioritization of In-house Drug Discovery Pipelines and Change in Use of Funds Raised at the Time of Listing”.

The corrected parts are indicated in double underlined.

Note

1. Reason and details of correction

This is a correction as errors were found in the details described in the table after the announcement of "Notice of Re-prioritization of In-house Drug Discovery Pipelines and Change in Use of Funds Raised at the Time of Listing".

2. Corrected parts

[Before correction]

Before change

Use of funds	Amount of money	Scheduled period of appropriation
1. Development costs for NIB101	1,900 million yen	Fiscal Year ended Dec. 31, 2023 - Fiscal Year ended Dec. 31, 2025
2. Costs for non-clinical trials of the pipelines after NIB104	60 million yen	Fiscal Year ended Dec. 31, 2023 - Fiscal Year ended Dec. 31, 2024
3. Research expenses for generation of new pipelines	330 million yen	Fiscal Year ended Dec. 31, 2023 - Fiscal Year ended Dec. 31, 2025
4. Research expenses for the new platform technologies	90 million yen	Fiscal Year ended Dec. 31, 2023 - Fiscal Year ended Dec. 31, 2025
Total	2,380 million yen	

After change

Use of funds	Amount of money	Scheduled period of appropriation
1. Development costs for NIB101	<u>530 million yen</u> (500 million yen)	Fiscal Year ended Dec. 31, 2023 - <u>Fiscal Year ended Dec. 31, 2024</u>
2. <u>Development costs for NIB103 (addition)</u>	<u>1,600 million yen</u> (-)	<u>Fiscal Year ended Dec. 31, 2024</u> - <u>Fiscal Year ended Dec. 31, 2026</u>

3. Costs for non-clinical trials of the pipelines after NIB104	<u>30 million yen</u> (30 million yen)	Fiscal Year ended Dec. 31, 2023 - Fiscal Year ended Dec. 31, 2024
4. Research expenses for generation of new pipelines	<u>130 million yen</u> (30 million yen)	Fiscal Year ended Dec. 31, 2023 - <u>Fiscal Year ended Dec. 31, 2026</u>
5. Research expenses for the new platform technologies	90 million yen (20 million yen)	Fiscal Year ended Dec. 31, 2023 - <u>Fiscal Year ended Dec. 31, 2026</u>
Total	2,380 million yen (580 million yen)	

Amounts in parentheses () are already appropriated

[After correction]

Before change

Use of funds	Amount of money	Scheduled period of appropriation
1. Development costs for NIB101	<u>1,977 million yen</u>	Fiscal Year ended Dec. 31, 2023 - Fiscal Year ended Dec. 31, 2025
2. Costs for non-clinical trials of the pipelines after NIB104	60 million yen	Fiscal Year ended Dec. 31, 2023 - Fiscal Year ended Dec. 31, 2024
3. Research expenses for generation of new pipelines	330 million yen	Fiscal Year ended Dec. 31, 2023 - Fiscal Year ended Dec. 31, 2025
4. Research expenses for the new platform technologies	90 million yen	Fiscal Year ended Dec. 31, 2023 - Fiscal Year ended Dec. 31, 2025
Total	<u>2,457 million yen</u>	

After change

Use of funds	Amount of money	Scheduled period of appropriation
1. Development costs for NIB101	<u>530 million yen</u> (500 million yen)	Fiscal Year ended Dec. 31, 2023 - <u>Fiscal Year ended Dec. 31, 2024</u>
2. <u>Development costs for NIB103 (addition)</u>	<u>1,677 million yen</u> (-)	<u>Fiscal Year ended Dec. 31, 2024</u> - <u>Fiscal Year ended Dec. 31, 2026</u>
3. Costs for non-clinical trials of the pipelines after NIB104	<u>30 million yen</u> (30 million yen)	Fiscal Year ended Dec. 31, 2023 - Fiscal Year ended Dec. 31, 2024
4. Research expenses for generation of new pipelines	<u>130 million yen</u> (30 million yen)	Fiscal Year ended Dec. 31, 2023 - <u>Fiscal Year ended Dec. 31, 2026</u>
5. Research expenses for the new platform technologies	90 million yen (20 million yen)	Fiscal Year ended Dec. 31, 2023 - <u>Fiscal Year ended Dec. 31, 2026</u>
Total	<u>2,457 million yen</u> (580 million yen)	

Amounts in parentheses () are already appropriated

【Noile-Immune Biotech Inc.】

Noile-Immune Biotech, Inc. (TSE: 4893) is a biotech company, an academia start-up, and is committed to the practical application of next-generation immunotherapy for solid cancers by utilizing PRIME CAR-T cells which incorporate Noile-Immune's proprietary PRIME technology, an innovative approach to enhance the therapeutic effects of immune cell therapy. As PRIME technology can be combined with various chimeric antigen receptors (CARs) to create novel drugs and applied to a broad range of modalities, it is expected to develop many anti-cancer therapeutic approaches in combination with other technologies in the future. Through our business activities, Noile-Immune aims to contribute to the creation of a society that can overcome cancer. For more information, please visit <https://www.noile-immune.com/en.html>.

Contact for inquiries or additional information

2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan

Noile-Immune Biotech, Inc.

E-mail: ir@noile-immune.com